Turning the Tide on Cancer
Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.
focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Jan 15, 2021
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program
Dec 21, 2020
Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board
Dec 6, 2020
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
Targeting PLK1, a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1) for the treatment of cancers with the greatest need for new treatment options.
PLK1 is over-expressed in most cancers. Inhibition of PLK1 causes mitotic arrest and subsequent cell death. Emerging data demonstrates that PLK1 is also a key regulator of cellular functions beyond mitosis that are essential for tumor growth.
Targeting a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.
Our Clinical Programs
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.